Dale L. Ludwig

7.7k total citations · 1 hit paper
91 papers, 5.9k citations indexed

About

Dale L. Ludwig is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Dale L. Ludwig has authored 91 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Molecular Biology, 35 papers in Radiology, Nuclear Medicine and Imaging and 21 papers in Oncology. Recurrent topics in Dale L. Ludwig's work include Monoclonal and Polyclonal Antibodies Research (26 papers), Growth Hormone and Insulin-like Growth Factors (16 papers) and Glycosylation and Glycoproteins Research (14 papers). Dale L. Ludwig is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (26 papers), Growth Hormone and Insulin-like Growth Factors (16 papers) and Glycosylation and Glycoproteins Research (14 papers). Dale L. Ludwig collaborates with scholars based in United States, Canada and Italy. Dale L. Ludwig's co-authors include Daniel J. Hicklin, Qing‐Bai She, José Baselga, Debra L. Smith, Heidi A. Lane, David B. Solit, Gordon B. Mills, Francesco Hofmann, Kathryn O’Reilly and Neal Rosen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Dale L. Ludwig

89 papers receiving 5.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt

2006 2.0k citations Kathryn O’Reilly, Qing‐Bai She et al. Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dale L. Ludwig United States	36	4.4k	1.6k	993	854	850	91	5.9k
Francesco Hofmann Switzerland	30	4.2k 1.0×	1.4k 0.9×	1.0k 1.1×	882 1.0×	900 1.1×	56	5.9k
Pnina Brodt Canada	46	3.2k 0.7×	2.5k 1.5×	2.2k 2.2×	1.3k 1.5×	689 0.8×	115	6.8k
Colin S. Cooper United Kingdom	31	3.9k 0.9×	1.6k 1.0×	1.6k 1.6×	395 0.5×	3.0k 3.6×	67	6.7k
Jeffrey A. Toretsky United States	46	4.7k 1.1×	1.7k 1.0×	864 0.9×	288 0.3×	1.7k 2.0×	121	6.9k
Junichi Kurebayashi Japan	37	1.8k 0.4×	1.9k 1.2×	999 1.0×	497 0.6×	425 0.5×	157	3.8k
Antonio Gualberto United States	35	3.1k 0.7×	1.6k 1.0×	1.3k 1.3×	1.2k 1.5×	925 1.1×	109	5.2k
Ricardo M. Attar United States	30	1.7k 0.4×	877 0.5×	652 0.7×	864 1.0×	827 1.0×	72	3.2k
Italia Bongarzone Italy	45	3.8k 0.9×	2.9k 1.7×	755 0.8×	3.3k 3.8×	500 0.6×	113	7.4k
Edward A. Fox United States	33	4.8k 1.1×	1.7k 1.0×	1.2k 1.2×	160 0.2×	709 0.8×	53	7.4k
Sandra E. Dunn Canada	43	3.5k 0.8×	1.5k 0.9×	1.1k 1.1×	625 0.7×	391 0.5×	99	5.1k

Countries citing papers authored by Dale L. Ludwig

Since Specialization

Citations

This map shows the geographic impact of Dale L. Ludwig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dale L. Ludwig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dale L. Ludwig more than expected).

Fields of papers citing papers by Dale L. Ludwig

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dale L. Ludwig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dale L. Ludwig. The network helps show where Dale L. Ludwig may publish in the future.

Co-authorship network of co-authors of Dale L. Ludwig

This figure shows the co-authorship network connecting the top 25 collaborators of Dale L. Ludwig. A scholar is included among the top collaborators of Dale L. Ludwig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dale L. Ludwig. Dale L. Ludwig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Khalil, Danny N., Michael A. Postow, Nageatte Ibrahim, et al.. (2016). An Open-Label, Dose–Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical Cancer Research. 22(21). 5204–5210. 19 indexed citations

Forest, Amélie, Dale L. Ludwig, Ying Wang, et al.. (2015). Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Molecular Cancer Research. 13(12). 1615–1626. 27 indexed citations

Li, Bin, Sai Wah Tsao, Kwok Wah Chan, et al.. (2014). Id1-Induced IGF-II and Its Autocrine/Endocrine Promotion of Esophageal Cancer Progression and Chemoresistance—Implications for IGF-II and IGF-IR–Targeted Therapy. Clinical Cancer Research. 20(10). 2651–2662. 65 indexed citations

Rowinsky, Eric K., Jonathan D. Schwartz, Naseem J. Zojwalla, et al.. (2011). Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers. Current Drug Targets. 12(14). 2016–2033. 23 indexed citations

Zhong, Zhaojing, Kyla Driscoll Carroll, Michael Gregory, et al.. (2009). Abstract #844: Anti-TGF beta receptor II antibody suppresses tumor growth and metastasis through inhibiting TGF beta autocrine stimulation of tumor cells and myeloid cells. Cancer Research. 69. 844–844. 1 indexed citations

Rowzee, Anne, Dale L. Ludwig, & Teresa L. Wood. (2009). Insulin-Like Growth Factor Type 1 Receptor and Insulin Receptor Isoform Expression and Signaling in Mammary Epithelial Cells. Endocrinology. 150(8). 3611–3619. 36 indexed citations

Prewett, Marie, et al.. (2007). IMC-A12 enhances the efficacy of cetuximab + gemcitabine therapy in human pancreatic carcinoma xenografts.. Cancer Research. 67. 652–652. 3 indexed citations

Kang, Xiaoqiang, et al.. (2007). High affinity Fc receptor binding and potent induction of antibody-dependent cellular cytotoxicity (ADCC) in vitro by anti-epidermal growth factor receptor antibody cetuximab. Journal of Clinical Oncology. 25(18_suppl). 3041–3041. 20 indexed citations

O’Reilly, Kathryn, Qing‐Bai She, David B. Solit, et al.. (2006). mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research. 66(3). 1500–1508. 2037 indexed citations breakdown →

10.

Rabenau, Karen E., Dan Lu, Paul Balderes, et al.. (2006). Therapeutic Implications of a Human Neutralizing Antibody to the Macrophage-Stimulating Protein Receptor Tyrosine Kinase (RON), a c-MET Family Member. Cancer Research. 66(18). 9162–9170. 105 indexed citations

11.

Best, Carolyn J.M., Dale L. Ludwig, & Patricia S. Steeg. (2006). Breast cancer cell lines resistant to either tamoxifen or Herceptin exhibit sensitivity to the anti-IGF receptor antibody A12 in vitro. Cancer Research. 66. 290–290. 4 indexed citations

12.

Liu, Meilin, Haifan Zhang, Xenia Jimenez, et al.. (2004). Identification and characterization of a fully human antibody directed against epidermal growth factor receptor for cancer therapy. Cancer Research. 64. 163–163. 14 indexed citations

13.

Wu, Yan, Zhaojing Zhong, Huiling Li, et al.. (2004). A fully human monoclonal antibody against VEGFR-1 inhibits growth of human breast cancers. Cancer Research. 64. 694–695. 1 indexed citations

14.

Ludwig, Dale L., Daniel S. Pereira, Zhenping Zhu, Daniel J. Hicklin, & Peter Böhlen. (2003). Monoclonal antibody therapeutics and apoptosis. Oncogene. 22(56). 9097–9106. 59 indexed citations

15.

Zheng, Rui, Mark J. Levis, Obdulio Piloto, et al.. (2003). FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood. 103(1). 267–274. 155 indexed citations

16.

Kussie, Paul, Jeffrey D. Hulmes, Dale L. Ludwig, et al.. (1999). Cloning and Functional Expression of a Human Heparanase Gene. Biochemical and Biophysical Research Communications. 261(1). 183–187. 170 indexed citations

17.

Ludwig, Dale L., Mark A. MacInnes, Yuichi Takiguchi, et al.. (1998). A murine AP-endonuclease gene-targeted deficiency with post-implantation embryonic progression and ionizing radiation sensitivity. Mutation Research/DNA Repair. 409(1). 17–29. 163 indexed citations

18.

Ludwig, Dale L., James R. Stringer, David C. Wight, Thomas Doetschman, & John Duffy. (1996). FLP-mediated site-specific recombination in microinjected murine zygotes. Transgenic Research. 5(6). 385–395. 10 indexed citations

19.

Ludwig, Dale L., et al.. (1993). High-level heterologous gene expression in Saccharomyces cerevisiae from a stable 2μm plasmid system. Gene. 132(1). 33–40. 17 indexed citations

20.

Ludwig, Dale L. & Carlo V. Bruschi. (1991). The 2-μm plasmid as a nonselectable, stable, high copy number yeast vector. Plasmid. 25(2). 81–95. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact